Cantor Fitzgerald initiated coverage on Wave Life Sciences with a new price target

4/29/25 8:13:21 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $WVE alert in real time by email

Cantor Fitzgerald initiated coverage of Wave Life Sciences with a rating of Overweight and set a new price target of $10.00

Get the next $WVE alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$WVE

Date	Price Target	Rating	Analyst
6/11/2025	$14.00	Outperform	Raymond James
4/29/2025	$10.00	Overweight	Cantor Fitzgerald
4/8/2025	$18.00	Outperform	Wedbush
2/25/2025	$26.00	Buy	Jefferies
10/16/2024	$22.00	Outperform → Strong Buy	Raymond James
9/27/2024	$10.00 → $13.00	Overweight	JP Morgan
9/19/2024	$11.00	Buy	B. Riley Securities
9/9/2024	$10.00	Overweight	JP Morgan

More analyst ratings

Cantor Fitzgerald initiated coverage on Wave Life Sciences with a new price target

Chat with this insight

Recent Analyst Ratings for
$WVE

$WVE
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Large owner Gsk Plc bought $22,335,440 worth of Ordinary Shares (2,791,930 units at $8.00) (SEC Form 4)

Gsk Plc bought $16,500,000 worth of Ordinary Shares (3,300,000 units at $5.00) (SEC Form 4)

Ra Capital Management, L.P. bought $5,000,000 worth of shares (1,000,000 units at $5.00) (SEC Form 4) (Amendment)

$WVE
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Raymond James resumed coverage on Wave Life Sciences with a new price target

Cantor Fitzgerald initiated coverage on Wave Life Sciences with a new price target

Wedbush initiated coverage on Wave Life Sciences with a new price target

$WVE
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Verdine Gregory L. sold $208,500 worth of Ordinary Shares (30,000 units at $6.95), decreasing direct ownership by 10% to 282,517 units (SEC Form 4)

Director Henry Christian O sold $102,574 worth of Ordinary Shares (10,500 units at $9.77) and exercised 10,500 units of Ordinary Shares at a strike of $9.13 (SEC Form 4)

President and CEO Bolno Paul exercised 169,025 units of Ordinary Shares at a strike of $2.48 and sold $1,617,569 worth of Ordinary Shares (169,025 units at $9.57) (SEC Form 4)

Cantor Fitzgerald initiated coverage on Wave Life Sciences with a new price target

Chat with this insight

Recent Analyst Ratings for $WVE

$WVE Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Large owner Gsk Plc bought $22,335,440 worth of Ordinary Shares (2,791,930 units at $8.00) (SEC Form 4)

Gsk Plc bought $16,500,000 worth of Ordinary Shares (3,300,000 units at $5.00) (SEC Form 4)

Ra Capital Management, L.P. bought $5,000,000 worth of shares (1,000,000 units at $5.00) (SEC Form 4) (Amendment)

$WVE Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Raymond James resumed coverage on Wave Life Sciences with a new price target

Cantor Fitzgerald initiated coverage on Wave Life Sciences with a new price target

Wedbush initiated coverage on Wave Life Sciences with a new price target

$WVE Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Verdine Gregory L. sold $208,500 worth of Ordinary Shares (30,000 units at $6.95), decreasing direct ownership by 10% to 282,517 units (SEC Form 4)

Director Henry Christian O sold $102,574 worth of Ordinary Shares (10,500 units at $9.77) and exercised 10,500 units of Ordinary Shares at a strike of $9.13 (SEC Form 4)

President and CEO Bolno Paul exercised 169,025 units of Ordinary Shares at a strike of $2.48 and sold $1,617,569 worth of Ordinary Shares (169,025 units at $9.57) (SEC Form 4)

Recent Analyst Ratings for
$WVE

$WVE
Insider Purchases

$WVE
Analyst Ratings

$WVE
Insider Trading